A paper co-written by Dr. Wayne Macfadden, former attending psychiatrist with the Princeton Healthcare Medical Center in Princeton, New Jersey, explores the costs patients with bipolar disorder incur to the Medicaid program. For this particular study, researchers looked at individuals with bipolar disorder type one, some of which required regular psychiatric interventions. Dr. Wayne Macfadden and his peers analyzed material from a Medicaid database to pinpoint patients who had more than two clinically significant events , such as hospitalizations or emergency room visits, linked to bipolar disorder in a year’s time. Such patients were classified as having received frequent psychiatric interventions (FPI).
According to the study, which was published in the Journal of Medical Economics, of the roughly 5,525 patients examined, 53 percent experienced FPIs. These patients were generally younger than those who did not require FPIs. Further, they incurred a higher cost to the Medicaid system than patients not requiring FPI.
This study appeared under the title “Characteristics, Healthcare Utilization and Costs of Bipolar Disorder Type I Patients with and Without Frequent Psychiatric Intervention in a Medicaid Population.”
From 2015 to 2018, I was a Global Medical Affairs Director for Novartis in their Ophthalmology division with Ranibizumab. Below are a few of the publications that resulted from my work there:
Systemic Safety in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration: A Patient-Level Pooled Analysis
Long-Term Outcomes of Ranibizumab Treatment of Myopic Choroidal Neovascularization In East-Asian Patients From the Radiance Study
Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study
It’s been a while since I posted, so this is a test blog from Philadelphia….
Wayne Macfadden MD
A Psychiatrist for over 25 years, Dr. Wayne Macfadden has held a variety of professional positions
Source: About Dr. Wayne Macfadden
Dr. Wayne Macfadden has practiced psychiatry for more than 25 years and takes a particular interest in bipolar disorder, a topic on which he has published extensively. Dr. Wayne Macfadden has authored several articles on the efficacy of the drug quetiapine as a monotherapy for bipolar disorder
Bipolar disorder is a highly recurrent and sometimes chronic mood disorder that presents as an alternation between periods of deep depression and periods of mania. It normally manifests in two forms: bipolar I, in which symptoms of depression exceed those of mania by a ration of about 3:1; and bipolar II, in which patients spend even more time in the depressive pole than the manic pole. Some bipolar patients experience rapid cycling or mood shifts between mania and depression that occur very quickly, usually within the course of a few hours. The mood swings associated with bipolar disorder can play havoc with a person’s energy and ability to function normally. While bipolar mania has dramatically disruptive effects, bipolar depression has been found to be even more detrimental and burdensome on patients and their families and loved ones.
Bipolar depression cannot generally be treated by antidepressants such as monotherapies (treatment of a condition using a single drug), unlike so-called “unipolar” major depression. However, the atypical antipsychotic drug quetiapine (commonly branded as Seroquel), usually recommended for treating the symptoms of schizophrenia, has been found to be effective as a monotherapy in treating bipolar depression. Quetiapine also appears to produce lower rates of treatment-emergent mania when used to treat bipolar depression, suggesting that it might be an effective mood stabilizer. It also appears to be effective in treating bipolar I and bipolar II depression, and for patients with or without histories of rapid cycling.
Wayne Macfadden, MD is a board certified psychiatrist in Haddonfield, New Jersey. He is currently licensed to practice medicine in New Jersey. He is affiliated with South Jersey Rad Associates, Quest – Haddonfield PSC, and South Jersey Rad Associates.